Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

Vonoprazan fulfilled the key endpoint for all 3 dosage degrees (10 mg, 20 mg, 40 mg) taken on-demand, showing faster as well as continual alleviation of anecdotal …

Read More …